Trial to study potential MMD treatment

January 1, 2005

Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.

Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.

The trial is an open-label, dose-ranging, international, multicenter study that will examine the safety and efficacy of CA4P in the treatment of MMD.

The drug attacks the vascular structure of solid tumors and other diseases characterized by the formation of aberrant blood vessels.